Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orvepitant for chronic cough in idiopathic pulmonary fibrosis: double-blind randomized placebo-controlled two-period crossover Phase 2 study
2021-006278-22Phase 2Completed
- Sponsor
- NeRRe Therapeutics
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of orvepitant in idiopathic pulmonary fibrosis (IPF) and chronic cough (2 arms), sponsored by NeRRe Therapeutics. Primary endpoint: Primary: Change in IPF Coughing Severity Scale score. Started Jun 2022; status: completed.
02
Drugs
orvepitant
03
Conditions
idiopathic pulmonary fibrosis (IPF)chronic cough
Beyond the preview
Go deeper on 2021-006278-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006278-22.